MedTrace Logo

Effects of High Dose Calcitriol in Breast Cancer Patients

NCT01293682 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2022-04-20

Study results available
· View outcomes & findings →

Summary

This research will examine the effectiveness of calcitriol in treating bone loss in women who are about to begin treatment for breast cancer. Twenty-five (25) subjects are expected to take part in this study. The investigators don't know if bone loss in breast cancer survivors should be treated differently than bone loss in other women.

Conditions

Interventions

DRUG

Calcitriol

In pill form, 45 micrograms once a week for 12 weeks

Sponsors & Collaborators

  • University of Rochester

    lead OTHER

Principal Investigators

  • Luke J Peppone, PhD · University of Rochester

  • Joseph J Guido, MS · Univ of Rochester

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
88 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-11-30
Primary Completion
2018-08-31
Completion
2021-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01293682 on ClinicalTrials.gov